Is Posterior Reversible Encephalopathy Syndrome Underestimated in Systemic Lupus Erythematosus?

To the Editor:

Varaprasad and colleagues described a cohort of reversible encephalopathy in patients with systemic lupus erythematosus (SLE)\(^1\). This cohort adds to the increasing evidence that SLE can manifest reversible encephalopathy, e.g., posterior reversible encephalopathy syndrome (PRES)\(^2,3\). It is possible that PRES is underestimated in SLE. However, we are concerned about the differential diagnoses of these cases.

PRES, also termed reversible posterior leukoencephalopathy syndrome, was initially described by Hinchey, \textit{et al}\(^4\) in 1996 as a clinico-radiological entity characterized by typical neurological deficits (headache, nausea and vomiting, altered mental status, visual impairment, and seizures), transient radiological brain anomalies, and a usually self-limited, benign and reversible clinical course. Different conditions might be attributable, such as eclampsia, hypertensive encephalopathy, renal diseases with hypertension, use of cyclosporine A or other immunosuppressive drugs\(^5,6\), etc. Other rare pathophysiological conditions, such as intracranial hypotension, have also been documented.

The pathophysiological mechanism of PRES is suggested to be vasogenic edema, arising from failure of cerebrovascular autoregulation and disruption of the blood-brain barrier\(^7\). Although signal hyperintensity can be seen in magnetic resonance imaging (MRI), and T2-weighted imaging and fluid-attenuated inversion recovery images may show abnormal signal intensity, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps are indispensable to differentiate vasogenic edema in PRES from cytotoxic edema as well as ischemia\(^8\).

Central nervous system (CNS) involvement in SLE is common. It can include vasculitis\(^9\), acute or subacute infarction\(^10\), and PRES\(^2,3\). Either lupus vasculitis or PRES may present with reversible lesions in the CNS. Therefore, reversible vasogenic edema as revealed by DWI and ADC maps, preferably involving the posterior white matter, can differentiate PRES from other reversible pathological changes in the CNS. For those patients with SLE who have neuropsychiatric manifestations, e.g., seizures, the reversible clinical symptoms and MRI anomalies may arise from epileptic seizures \textit{per se}, rather than PRES. Since a well-acknowledged set of diagnostic criteria for PRES is lacking, we wonder whether the authors considered other SLE-associated reversible lesions as the differential diagnoses. A failure to do so may lead to an overestimation of PRES in SLE.

PRES does appear to be underestimated in SLE. However, the diagnosis of PRES might be confounded by other reversible pathological changes in SLE.

REFERENCES


J Rheumatol 2011;38:11; doi:10.3899/jrheum.110762